These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36463978)

  • 1. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
    Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
    Front Immunol; 2022; 13():907125. PubMed ID: 35784359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.
    Hickey TE; Kemp TJ; Bullock J; Bouk A; Metz J; Neish A; Cherry J; Lowy DR; Pinto LA
    Hum Vaccin Immunother; 2023 Aug; 19(2):2215677. PubMed ID: 37264688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination.
    Steiner S; Schwarz T; Corman VM; Jeworowski LM; Bauer S; Drosten C; Scheibenbogen C; Hanitsch LG
    J Clin Immunol; 2023 Jul; 43(5):869-881. PubMed ID: 36932291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.
    Pulvirenti F; Di Cecca S; Sinibaldi M; Piano Mortari E; Terreri S; Albano C; Guercio M; Sculco E; Milito C; Ferrari S; Locatelli F; Quintarelli C; Carsetti R; Quinti I
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
    Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
    J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.
    Nakagama Y; Candray K; Kaku N; Komase Y; Rodriguez-Funes MV; Dominguez R; Tsuchida T; Kunishima H; Nagai E; Adachi E; Ngoyi DM; Yamasue M; Komiya K; Hiramatsu K; Uemura N; Sugiura Y; Yasugi M; Yamagishi Y; Mikamo H; Shiraishi S; Izumo T; Nakagama S; Watanabe C; Nitahara Y; Tshibangu-Kabamba E; Kakeya H; Kido Y
    J Infect Dis; 2023 Mar; 227(6):780-787. PubMed ID: 36546706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
    Nielsen BU; Drabe CH; Barnkob MB; Johansen IS; Hansen AKK; Nilsson AC; Rasmussen LD
    Front Immunol; 2022; 13():934476. PubMed ID: 35967433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults.
    Rastawicki W; Juszczyk G; Gierczyński R; Zasada AA
    J Clin Virol; 2022 Jul; 152():105193. PubMed ID: 35660747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.
    Milota T; Smetanova J; Skotnicova A; Rataj M; Lastovicka J; Zelena H; Parackova Z; Fejtkova M; Kanderova V; Fronkova E; Rejlova K; Sediva A; Kalina T
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):306-314.e2. PubMed ID: 36379409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
    Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
    Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination.
    Page L; Dennehy K; Mueller K; Girl P; Loell E; Buijze H; Classen JM; Messmann H; Roemmele C; Hoffmann R; Wurster S; Fuchs A
    Front Immunol; 2024; 15():1423766. PubMed ID: 39267758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.